Skip to content

Effects of Low-Dose Theophylline During Chronic Obstructive Pulmonary Disease (COPD) Exacerbations

Molecular Mechanisms of COPD Exacerbations. Effect of Low-Dose Theophylline

Status
Completed
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT00671151
Enrollment
35
Registered
2008-05-05
Start date
2005-06-30
Completion date
2007-12-31
Last updated
2008-05-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

COPD

Keywords

COPD exacerbation, histone, steroid resistance, inflammation, theophylline

Brief summary

Molecular mechanisms of COPD exacerbations and the modulating effect of low dose theophylline on that inflammation are elucidated in this project. NF-kappa B-dependent pathway and acetylation status of nuclear histones are to be studied.Design: controlled, prospective and randomized study with or without theophylline, a potent HDAC activator.Objectives: 1) To determine NF-kB activation, histone deacetylase (HDAC) and histone acetyl-transferase (HAT) activity in sputum macrophages and blood monocytes during an episode of exacerbation and 3 months later, once stability is achieved. To correlate these measurements with inflammatory and oxidative stress markers and with pulmonary function and clinical variables. 2) To assess the effect of theophylline on previous molecular, functional and clinical data. Method: 25 patients with COPD will be recruited during an episode of exacerbation requiring hospitalization. NF-kB activation, HDAC and HAT activity, markers of inflammation and oxidative stress will be determined with specific assays. These determinations will be repeated once the patient is stable and compared with smokers and non smoker controls with normal lung function

Interventions

DRUGTheophylline

Theophylline 100 mg bid for 3 months

Sponsors

Fondo de Investigación Sanitaria (FIS)
CollaboratorUNKNOWN
Sociedad Española de Neumología y Cirugía Torácica
CollaboratorOTHER
Hospital Universitari Son Dureta
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender
MALE
Age
40 Years to 75 Years
Healthy volunteers
Yes

Inclusion criteria

* Severe COPD according to GOLD guidelines * Age between 40 and 75 * Admission to hospital due to COPD exacerbation

Exclusion criteria

* History of asthma * Pulmonary embolism * Pneumonia * Other chronic inflammatory disease * Patient on theophylline at the time of admission * Patient on oral steroids at the time of admission

Design outcomes

Primary

MeasureTime frame
HDAC activity in alveolar macrophages3 months

Secondary

MeasureTime frame
Lung function3 months
Inflammatory cytokine release in sputum and serum3 months

Countries

Spain

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Apr 3, 2026